The FDA granted Breakthrough Therapy designation to INCA033989 for the treatment of patients with ET harboring a Type 1 CALR mutation who are resistant or intolerant to at least one cytoreductive ...
The CBSE acknowledges potential minor errors in Class XII answer sheet evaluations, processing millions annually. Students ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results